Jordi Bartle-Craven

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy.

Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 16, 2020

RNA sequencing and Immunohistochemistry Reveal ZFN7 as a Stronger Marker of Survival than Molecular Subtypes in G-CIMP-negative Glioblastoma.

RNA sequencing and Immunohistochemistry Reveal ZFN7 as a Stronger Marker of Survival than Molecular Subtypes in G-CIMP-negative Glioblastoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 16, 2020

Pseudoprogression as an adverse event of glioblastoma therapy.

Pseudoprogression as an adverse event of glioblastoma therapy.

Journal: Cancer medicine

Published: July 25, 2017

The usefulness of 18F-fluorocholine PET/CT in the detection of recurrence of central nervous system primary neoplasms.

The usefulness of 18F-fluorocholine PET/CT in the detection of recurrence of central nervous system primary neoplasms.

Journal: Revista espanola de medicina nuclear e imagen molecular

Published: October 11, 2016

Association between single-nucleotide polymorphisms in DNA double-strand break repair genes and prostate cancer aggressiveness in the Spanish population.

Association between single-nucleotide polymorphisms in DNA double-strand break repair genes and prostate cancer aggressiveness in the Spanish population.

Journal: Prostate cancer and prostatic diseases

Published: September 22, 2015

Pelvic MRI findings in relapsed prostate cancer after radical prostatectomy.

Pelvic MRI findings in relapsed prostate cancer after radical prostatectomy.

Journal: Radiation oncology (London, England)

Published: September 01, 2015

Intraethnic variation in steroid-5-alpha-reductase polymorphismsin prostate cancer patients: a potential factor implicated in 5-alpha-reductase inhibitor treatment.

Intraethnic variation in steroid-5-alpha-reductase polymorphismsin prostate cancer patients: a potential factor implicated in 5-alpha-reductase inhibitor treatment.

Journal: Journal of genetics

Published: July 16, 2015

Genetic variations in genes involved in testosterone metabolism are associated with prostate cancer progression: A Spanish multicenter study.

Genetic variations in genes involved in testosterone metabolism are associated with prostate cancer progression: A Spanish multicenter study.

Journal: Urologic oncology

Published: February 25, 2015

Single nucleotide polymorphisms in DNA repair genes as risk factors associated to prostate cancer progression.

Single nucleotide polymorphisms in DNA repair genes as risk factors associated to prostate cancer progression.

Journal: BMC medical genetics

Published: September 24, 2014

Polymorphisms in DNA-repair genes in a cohort of prostate cancer patients from different areas in Spain: heterogeneity between populations as a confounding factor in association studies.

Polymorphisms in DNA-repair genes in a cohort of prostate cancer patients from different areas in Spain: heterogeneity between populations as a confounding factor in association studies.

Journal: PloS one

Published: May 02, 2013

Showing 1-10 of 10

Last Updated: 09/26/2026